{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016511","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.471298+00:00","generated_at":"2026-06-15T02:31:22.331433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmatrix reports Q1 net loss $4.45M; cash runway extended to Q4 2024","bullets":["Net loss of $4.45M ($1.22 per share) vs $4.97M loss in Q1 2022.","Revenue $1.5M, up from $1.2M, mainly from Cipla agreement.","Cash $30.8M; projected runway extended from Q2 2024 to Q4 2024.","Phase 2b PUR1900 trial dosing initiated for ABPA; topline data expected mid-2024.","Phase 1 PUR3100 migraine study positive; IND filing planned mid-2023, Phase 2 pending financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016511","json":"https://secwatch.observer/filing/0001493152-23-016511.json","markdown":"https://secwatch.observer/filing/0001493152-23-016511.md","text":"https://secwatch.observer/filing/0001493152-23-016511.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:31:22.331433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40563c6250bb9a65706260d0d88a16099755db4e","claim":"Pulmatrix, Inc. reported the three months ended March 31, 2023 results: revenue $1.5 million.","evidence_excerpt":"Revenues increased $0.3 million to $1.5 million for the three months ended March 31, 2023 compared to $1.2 million for the three months ended March 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4a45324eb31261d70f80e6875c54cbf9346e34d2","claim":"Pulmatrix, Inc. reported financial results for the first fiscal quarter ended March 31, 2023.","evidence_excerpt":"On May 12, 2023, Pulmatrix, Inc. (the “Company”) issued a press release announcing its financial results for the first fiscal quarter ended March 31, 2023 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315223016511/0001493152-23-016511-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first fiscal quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}